Jyong Biotech Ltd.
MENS evidence brief
What we can confirm
- Market Cap:
- $151.3M
What it means
What to watch
Prepared research question
What matters most for MENS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MENS
Jyong Biotech Ltd. is a Taiwan-based science-driven biotechnology company focused on developing and commercializing innovative drugs for urinary system diseases, with a pipeline of botanical drug candidates including Botreso® for BPH/LUTS and PCP for prostate cancer prevention.
Key risk: API comparability risk
Market Cap
$151.3M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Dec 31, 2025.
Jyong Biotech Ltd. is a Taiwan-based science-driven biotechnology company focused on developing and commercializing innovative drugs for urinary system diseases, with a pipeline of botanical drug candidates including Botreso® for BPH/LUTS and PCP for prostate cancer prevention.
- Jyong Biotech is a science-driven biotechnology company based in Taiwan, specializing in urinary system diseases [sec · filed 2026-05-15].
- Its pipeline includes three drug candidates: Botreso® (BPH/LUTS), PCP (prostate cancer prevention), and IC (preclinical) [sec · filed 2026-05-15].
- PCP completed Phase II in Taiwan with data lock in May 2025 and statistical analysis in September 2025 [sec · filed 2026-05-15].
- The company's pivotal Phase III trial for Botreso® in the U.S. failed to show a difference for the primary efficacy endpoint [sec · filed 2026-05-15].
- As of 2025-12-31, shareholders' equity was -$24.9M and total debt was $17.5M [sec].
What works
- Jyong has built fully integrated in-house capabilities covering drug discovery, development, and clinical trials, which positions it for pharmaceutical innovation [sec · filed 2026-05-15].
- The company holds 31 invention patents in 19 territories and 58 trademarks in 46 territories, indicating a strong intellectual property portfolio [sec · filed 2026-05-15].
- Jyong has a co-commercialization agreement for Botreso® in Cambodia, leveraging strategic partners' sales networks [sec · filed 2026-05-15].
What to weigh
- The pivotal Phase III trial for Botreso® in the U.S. failed to show a difference between treatment groups for the primary efficacy endpoint [sec · filed 2026-05-15].
- The company faces risk of needing to repeat clinical trials if API-1 and API-2 are not deemed comparable by the FDA [sec · filed 2026-05-15].
- Existing cash on hand is not sufficient to meet short-term obligations or long-term plans, including commercialization or future clinical trials [sec · filed 2026-05-15].
- As of 2025-12-31, shareholders' equity was negative (-$24.9M) and total debt was $17.5M, indicating financial strain [sec].
From the filings
Quoted directly from source documents.
Company focus on urinary system diseases
“committed to developing and commercializing innovative and differentiated new drugs mainly specializing in the treatment of urinary system diseases”
SEC filings · May 15, 2026
Phase III trial failure for Botreso®
“Our pivotal Phase III clinical trial for Botreso ® in the U.S. failed to show a difference between treatment groups for the primary efficacy endpoint in the intent-to-treat population.”
SEC filings · May 15, 2026
PCP Phase II completion
“PCP, has completed the phase II clinical trial in Taiwan, with data lock in May 2025 and statistical analysis completed in September 2025.”
SEC filings · May 15, 2026
Cash insufficiency
“Our existing cash on hand will not be sufficient to enable us to meet our short-term obligations or long-term plans”
SEC filings · May 15, 2026
Risks & what to watch (4)›
Key risks
- API comparability risk — If API-1 and API-2 are not comparable, Jyong may need to repeat Botreso® and PCP clinical trials [sec · filed 2026-05-15].
- Cash runway insufficient — Existing cash on hand cannot meet short-term obligations or long-term plans [sec · filed 2026-05-15].
- Negative equity and debt — Shareholders' equity -$24.9M and total debt $17.5M as of 2025-12-31 [sec].
- Regulatory approval delays — All drug candidates are in development; failure to obtain approval would materially harm business [sec · filed 2026-05-15].
What to watch
- FDA response to Jyong's WRO meeting request and review of the new drug development program for API-2 [sec · filed 2026-05-15].
- Outcome of comparability studies between API-1 and API-2, which could force repeat of clinical trials [sec · filed 2026-05-15].
- Jyong's ability to raise additional capital given insufficient cash on hand [sec · filed 2026-05-15].
- Progress of PCP toward potential Phase III trials after Phase II completion in September 2025 [sec · filed 2026-05-15].
Sources: SEC filings · Generated October 3, 2026 · How we verify sources →
Run Jyong Biotech Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Jyong Biotech Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
17
Total value held
$949K
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 258,760 | $556K |
| geode capital management, llc | 64,232 | $138K |
| ubs group ag | 37,363 | $80K |
| millennium management llc | 14,590 | $31K |
| vanguard personalized indexing management, llc | 13,927 | $30K |
| china universal asset management co., ltd. | 13,173 | $28K |
| tower research capital llc (trc) | 11,703 | $25K |
| morgan stanley | 6,301 | $14K |
| barclays plc | 5,189 | $11K |
| jpmorgan chase & co | 5,679 | $11K |
Showing top 10 of 17 institutional holders of Jyong Biotech Ltd.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 0.5%
- Days to cover
- 1.7
- Shares short
- 194,489
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MENS short interestFrequently asked questions
What is the AI investment thesis for Jyong Biotech Ltd.?
Jyong Biotech Ltd. is a Taiwan-based science-driven biotechnology company focused on developing and commercializing innovative drugs for urinary system diseases, with a pipeline of botanical drug candidates including Botreso® for BPH/LUTS and PCP for prostate cancer prevention.
Who is the CEO of Jyong Biotech Ltd.?
Ms. Fu-Feng Kuo is the chief executive officer of Jyong Biotech Ltd. (MENS).
Where is Jyong Biotech Ltd. headquartered?
Jyong Biotech Ltd. (MENS) is headquartered in New Taipei City, Taiwan.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.